The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Novel BTK inhibitors for Waldenström’s macroglobulinemia
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenström’s macroglobulinemia (WM) from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Garcia-Sanz comments on the current limitations of treatments available for WM, including toxicities and the need for multiple agents. Novel BTK inhibitors hold promise for these patients, with ibrutinib in combination with rituximab showing positive results when compared to rituximab alone.
